Gabapentin - CAS 60142-96-3
Catalog number:
60142-96-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C9H17NO2
Molecular Weight:
171.24
COA:
Inquire
Targets:
Calcium Channel
Description:
Gabapentin is structurally similar to GABA and is reported in various research studies to increase GABA concentrations within the brain. Gabapentin is also noted to bind to a novel site on voltage-sensitive Ca2+ channels. Additionally, Gabapentin is reported to demonstrate inhibition of dopamine release from caudate nucleus, prevent neuronal cell death, and is antinociceptive.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome.
Avidan AY1, Lee D2, Park M3, Jaros MJ4, Shang G5, Kim R5. CNS Drugs. 2016 Apr 11. [Epub ahead of print]
OBJECTIVE: The aim was to assess gabapentin enacarbil (GEn) treatment effects on quality of life (QOL) and mood in adults with moderate-to-severe primary restless legs syndrome (RLS).
2.Gabapentin for the Management of Chronic Pelvic Pain in Women (GaPP1): A Pilot Randomised Controlled Trial.
Lewis SC1, Bhattacharya S2, Wu O3, Vincent K4, Jack SA5, Critchley HO6, Porter MA2, Cranley D7, Wilson JA8, Horne AW6. PLoS One. 2016 Apr 12;11(4):e0153037. doi: 10.1371/journal.pone.0153037. eCollection 2016.
TRIAL REGISTRATION: Controlled-Trials.com ISRCTN45178534.
3.Diabetic Sensory and Motor Neuropathy.
N Engl J Med. 2016 Apr 13. [Epub ahead of print]
Diabetic Sensory and Motor Neuropathy Clinical Practice, N Engl J Med 2016;374:1455-1464. In Table 1 (page 1457), in the second entry in the third column, "impaired autonomic dysfunction" should have been "impaired autonomic function." The third entry in the first column should have been "Recognize clinical implications." The fifth entry in the first column should have been "Consider differential diagnosis." In Table 2 (pages 1460-1), the initial dose of topiramate should have been 25 mg/day, and the effective dose 25-100 mg/day. For gabapentin, the upper bound of the confidence interval for the number needed to treat should have been 8.3. The effective dose of amitriptyline should have been 25-150 mg/day. The effective dose of tramadol should have been 100-200 mg/day, and the number needed to treat should have been 4.7. In the final sentence of the second paragraph under Areas of Uncertainty (page 1461), the term "(frank deficiency)" should not have appeared.
4.Analyzing Relationship Between Monoclonal Gammopathy of Undetermined Significance (MGUS) with Different Types of Neuropathy: An Observational Study.
Nabi S1, Kahlon P1, Bozorgnia F2, Arshad A3, Saleem A4, Kuriakose P5. Indian J Hematol Blood Transfus. 2016 Jun;32(2):186-92. doi: 10.1007/s12288-015-0547-9. Epub 2015 May 28.
To analyze multiple variables, including immunoglobulin subtypes in patients with monoclonal gammopathy of undetermined significance (MGUS) and different types of neuropathy. This was a retrospective, single center study done in a tertiary care hospital in the United States. The data was collected for years 2001-2011. Inclusion criteria were the presence of MGUS and neuropathy. Exclusion criteria were the presence of other factors such as diabetes, vitamin B12 deficiency, alcoholism etc. which can cause neuropathy. Patients with IgM MGUS were compared with patients having Non-IgM MGUS. A total of 281 patients were analyzed in this study. The average age at the time of diagnosis of MGUS and neuropathy was 68 years. The most common type of neuropathy was sensorimotor peripheral neuropathy (46 %). The most common location of neuropathy was the lower extremities (68 %). Among our patients, 52 % had their neuropathy symptoms for 1-5 years before presenting to the clinic.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Calcium Channel Products


S(-)-BAY K 8644
(CAS: 98625-26-4)

S(-)-BAY K 8644 is an activator of voltage-sensitive L-type calcium channels with positive inotropic, vasoconstrictive and behavioral effects in vivo. It is the...

CAS 68291-97-4 Zonisamide

Zonisamide
(CAS: 68291-97-4)

Zonisamide is the first agent of this chemical class to be developed as an antiepileptic drug blocks repetitive firing of voltagesensitive sodium channels and r...

CAS 152-11-4 Verapamil HCl

Verapamil HCl
(CAS: 152-11-4)

Verapamil HCl is an L-type calcium channel blocker that is a class IV anti-arrhythmia agent.

CAS 136-47-0 Tetracaine Hydrochloride

Tetracaine Hydrochloride
(CAS: 136-47-0)

Tetracaine hydrochlorideis a hydrochloride salt form of tetracaine which is a potent local anaesthetic and a channel function allosteric inhibitor.

CAS 129198-88-5 Autocamtide 2

Autocamtide 2
(CAS: 129198-88-5)

Autocamtide 2 is a highly selective synthetic peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activit...

CAS 298-57-7 Cinnarizine

Cinnarizine
(CAS: 298-57-7)

Cinnarizine, with antiallergic and anti-vasoconstricting activity, is a calcium channel blocker to treat cerebral apoplexy, post-trauma cerebral symptoms, and c...

CAS 132203-70-4 Cilnidipine

Cilnidipine
(CAS: 132203-70-4)

Cilnidipine is a unique L-type and N-type calcium channel blocker, used for high blood pressure treatment.

OPC 13463
(CAS: 73372-63-1)

OPC 13463 is one of the metabolites of pranidipine. Pranidipine is a long acting calcium channel antagonist of the dihydropyridine group.

CAS 132866-11-6 Lercanidipine Hydrochloride

Lercanidipine Hydrochloride
(CAS: 132866-11-6)

The hydrochloride salt form of Lercanidipine, a dihydropyridine derivative, could be used as an antihypertensive agent through influencing the L-type Ca2+ chann...

CAS 248922-46-5 PD0176078

PD0176078
(CAS: 248922-46-5)

PD0176078 is a novel N-type calcium channel blocker.

CAS 13636-18-5 Fendiline hydrochloride

Fendiline hydrochloride
(CAS: 13636-18-5)

The hydrochloride salt form of Fendiline, a benzenepropanamine derivative, has been found to be a calcium channel blocker and alpha2-adrenergic receptor antagon...

CAS 79700-61-1 Dopropidil

Dopropidil
(CAS: 79700-61-1)

Dopropidil, also called as ORG 30701, is a cardioactive drug to be classified as a calcium antagonist with combined class I and class VI antiarrhythmic properti...

CAS 77-41-8 METHSUXIMIDE

METHSUXIMIDE
(CAS: 77-41-8)

Mesuximide is a succinimide anticonvulsant medication. The therapeutic efficacy of methosuximide is due to its pharmacologically active metabolite, N-desmethylm...

CAS 75530-68-6 Nilvadipine

Nilvadipine
(CAS: 75530-68-6)

Nilvadipine is a potent calcium channel blocker with an IC50 of 0.03 nM.

CAS 136941-70-3 Calcium channel-modulator-1

Calcium channel-modulator-1
(CAS: 136941-70-3)

A calcium channel modulator that blocks aortic contraction (IC50= 0.8 μM)

CAS 125697-93-0 Lavendustin C

Lavendustin C
(CAS: 125697-93-0)

Lavendustin C, also known as HDBA and NSC 666251, inhibits Ca2+/CaMKII (calmodulin kinase II) (IC50=0.2 μM), EGFR tyrosine kinase (IC50=44 nM) and SRC (IC50=0.5...

CAS 357400-13-6 NNC 55-0396 dihydrochloride

NNC 55-0396 dihydrochloride
(CAS: 357400-13-6)

NNC 55-0396 is a derivative of Mibefradil as a T-type calcium channel blocker (IC50=6.8 nM)

CAS 39562-70-4 Nitrendipine

Nitrendipine
(CAS: 39562-70-4)

Nitrendipine is a dihydropyridine calcium channel blocker with an IC50 of 95 nM.It is used in the treatment of primary (essential) hypertension to decrease bloo...

CAS 91599-74-5 Benidipine HCl

Benidipine HCl
(CAS: 91599-74-5)

Benidipine HCl is a hydrochloride salt form of benidipine which is a dihydropyridine calcium channel blocker.

CAS 111011-53-1 EFONIDIPINE HCL

EFONIDIPINE HCL
(CAS: 111011-53-1)

The hydrochloride salt form of Efonidipine which could be effective in the treatment of cardiovascular disease as a blocker of T-type and L-type calcium channel...

Chemical Structure

CAS 60142-96-3 Gabapentin

Quick Inquiry

Verification code

Featured Items